Wire · opportunities
FDA expands Bristol Myers Squibb's Camzyos into pediatric obstructive hypertrophic cardiomyopathy
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 2 October 2026 · Fusion42 review
The US FDA has expanded approval of Bristol Myers Squibb's Camzyos (mavacamten) to treat pediatric patients aged 12 and older with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), making it the first FDA-approved therapy for pediatric oHCM.
This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 30 Sep 2026 and 1 Oct 2026.
◆ ◆ The Wire takeaway
You have a new FDA-approved drug to treat pediatric hypertrophic cardiomyopathy, opening fresh market opportunities in heart disease care for younger patients and a chance to set early treatment standards.
◆ Coverage
3 sources · first reported 30 Sep 2026 · latest 1 Oct 2026
◆ Related on Wire
◆ Topics